Skip to main content

Transgenomic Secures $7.5M in Revolving Credit

NEW YORK, Dec. 9 (GenomeWeb News) - Transgenomic said today that it has entered into an agreement for up to $7.5 million in a revolving line of credit with Laurus Master Fund.

Transgenomic said it would have access to the funds based on eligible accounts receivable and inventory balances. The arrangement replaces a previous $5.0 million line of credit from a commercial bank that had a higher interest rate, the company said.

Under the terms of the agreement, Transgenomic issued warrants to Laurus Funds to acquire up to 550,000 shares of its stock at a price based on a premium to the average trading price of its common stock for ten trading days prior to execution of the agreement.

In August, Transgenomic raised $4.5 million in a private placement with a number of investors.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.